Global Erythropoietic Protoporphyria Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Erythropoietic Protoporphyria Drugs Market Research Report 2024
EPP is a rare genetic disease. Due to the defect of heme biosynthesis, excessive protoporphyrin IX (PPIX) is accumulated and stored in the blood and tissues of patients. When exposed to visible light and near visible ultraviolet radiation, PPIX is activated by light, causing photosensitive damage to surrounding tissues and causing unbearable pain. The disease is a skin photophobia. The patient cannot see the light. After being exposed to sunlight or artificial light, the patient will experience serious biochemical reactions, resulting in skin burns, ulcers and phototoxicity.
According to Mr Accuracy reports’s new survey, global Erythropoietic Protoporphyria Drugs market is projected to reach US$ 866.8 million in 2029, increasing from US$ 585 million in 2022, with the CAGR of 5.8% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Erythropoietic Protoporphyria Drugs market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Erythropoietic Protoporphyria Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
CLINUVEL PHARMACEUTICALS LTD
Johnson & Johnson Private Limited
Tishcon Corporation
L'Oréal S.A
Fenton Pharmaceuticals Ltd
Mylan N.V
Pfizer Inc
Abbvie Inc
Novartis AG
Sun Pharmaceutical Industries Ltd
Teva Pharmaceuticals Industries Ltd
Segment by Type
External Drugs
Oral Medicine
Hospitals
Specialty Clinics
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Erythropoietic Protoporphyria Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Erythropoietic Protoporphyria Drugs market is projected to reach US$ 866.8 million in 2029, increasing from US$ 585 million in 2022, with the CAGR of 5.8% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Erythropoietic Protoporphyria Drugs market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Erythropoietic Protoporphyria Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
CLINUVEL PHARMACEUTICALS LTD
Johnson & Johnson Private Limited
Tishcon Corporation
L'Oréal S.A
Fenton Pharmaceuticals Ltd
Mylan N.V
Pfizer Inc
Abbvie Inc
Novartis AG
Sun Pharmaceutical Industries Ltd
Teva Pharmaceuticals Industries Ltd
Segment by Type
External Drugs
Oral Medicine
Segment by Application
Hospitals
Specialty Clinics
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Erythropoietic Protoporphyria Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices